Taiga Biotechnologies
Aurora
About Taiga Biotechnologies
Taiga Biotechnologies is a clinical-stage company focused on harnessing the immune system to fight infectious disease and cancer. The company's Bone Marrow Engraftment Enhancer (BMEE) program is developing a first-line product, TBX-1400, to enhance the engraftment of hematopoietic stem and progenitor cells during an allogeneic hematopoietic stem cell transplant (HSCT). Taiga Biotechnologies lead Cell-Based Immunotherapy product candidate, TBX-3400, uses a patient’s own immune cells to help fight against cancer and infectious disease. TBX-3400 is an autologous cell product made from peripheral blood mononuclear cells that are treated ex vivo with our fusion protein and then delivered intravenously back to the patient the following day. They developing technologies to generate red blood cells in the laboratory for clinical applications and products to improve the utility of red blood cell products.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $52.3M
- Last round: Debt Financing (Aug 2020)
- Website: taigabiotech.com
- Phone: (720) 859-3547
Industries & Categories
Biotechnology, Life Science, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/taiga-biotechnologies-69465 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.